BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways

Stock Information for BiomX Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BiomX Inc.

BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis
BiomX Inc. Announces 1-for-19 Reverse Stock Split
BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates
BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025
BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections
BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference
BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.